First, Yigit et al. demonstrated that anti-SLAMF6 treatment improved in vivo T cell activity against chronic lymphocytic leukemia and melanoma by opposing the increase in exhaustion-related receptors, such as PD-1 [39]. Here, SLAMF6 is linked to melanoma.